State

Northern Mariana Islands product recalls

73,827 recalls have nationwide distribution and so reach Northern Mariana Islands. 23 additional recalls listed Northern Mariana Islands specifically in their distribution scope.

What the numbers show

Total: 23
Critical: 0
Severe: 18
Most recent: 2026-09-23

Of the 23 recalls naming Northern Mariana Islands we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 18 (78%) are Severe.

Which agencies issued them

These figures cover only the 23 recalls whose distribution notice names Northern Mariana Islands specifically. The 73,827 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.

53976–54000 of 73850

SevereFDA (Drugs)·D-859-2015·2015-04-29
Attix Pharmaceuticals Recalls Pregabalin Ingredient Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling pregabalin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Pregabalin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-643-2015·2015-04-29
Attix Pharmaceuticals Recalls Doxycycline Monohydrate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Doxycycline Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Doxycycline Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-956-2015·2015-04-29
Attix Pharmaceuticals Recalls Zidovudine API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Zidovudine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Zidovudine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-836-2015·2015-04-29
Attix Pharmaceuticals Recalls Pentosan Polysulfate Sodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Pentosan Polysulfate Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Pentosan Polysulfate Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-657-2015·2015-04-29
Attix Pharmaceuticals Recalls Estriol Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Estriol active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Estriol (Ultra-Micronized) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-818-2015·2015-04-29
Attix Pharmaceuticals Recalls Nitazoxanide Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Nitazoxanide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Nitazoxanide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-926-2015·2015-04-29
Attix Pharmaceuticals Recalls Thimerosal Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Thimerosal active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Thimerosal active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-856-2015·2015-04-29
Prednisolone Anhydrous Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Prednisolone Anhydrous active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.
Product
Prednisolone Anhydrous active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-805-2015·2015-04-29
Attix Pharmaceuticals Recalls Mometasone Furoate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Mometasone Furoate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Mometasone Furoate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-496-2015·2015-04-29
Attix Pharmaceuticals Recalls DMSA Ingredient Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling 2,3-Dimercaptosuccinic Acid (DMSA) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
2,3-Dimercaptosuccinic Acid (DMSA) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-625-2015·2015-04-29
Attix Pharmaceuticals Recalls Dexchlorpheniramine Maleate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Dexchlorpheniramine Maleate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Dexchlorpheniramine Maleate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-663-2015·2015-04-29
Attix Pharmaceuticals Recalls Etidronate Disodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Etidronate Disodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Etidronate Disodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-942-2015·2015-04-29
Attix Pharmaceuticals Recalls Tretinoin Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Tretinoin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Tretinoin or All-Trans Retinoic Acid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-675-2015·2015-04-29
Attix Pharmaceuticals Recalls Flibanserin API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Flibanserin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Flibanserin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-771-2015·2015-04-29
Attix Pharmaceuticals Recalls Magnesium Stearate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Magnesium Stearate pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Magnesium Stearate pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-897-2015·2015-04-29
Attix Pharmaceuticals Recalls Sodium Dichloroacetate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Sodium Dichloroacetate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Sodium Dichloroacetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-822-2015·2015-04-29
Attix Pharmaceuticals Recalls Olsalazine Sodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Olsalazine Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Olsalazine Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-813-2015·2015-04-29
Attix Pharmaceuticals Recalls Naproxen Sodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Naproxen Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Naproxen Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-946-2015·2015-04-29
Attix Pharmaceuticals Recalls Uridine-5'Triphosphate Trisodium Salt Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Uridine-5'Triphosphate Trisodium Salt active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Uridine-5'Triphosphate Trisodium Salt active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-890-2015·2015-04-29
Attix Pharmaceuticals Recalls Seratonin HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Seratonin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed nationwide to compounding pharmacies and research organizations.
Product
Seratonin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Devices)·Z-1456-2015·2015-04-29
OriGen VV13F Reinforced Dual Lumen Catheter Recalled for Separation Risk
OriGen Biomedical is recalling 51 units of VV13F Reinforced Dual Lumen Catheters because the extension tube may separate from the hub, posing a risk of blood loss.
Product
OriGen BIOMEDICAL VV13F Reinforced Dual Lumen Catheter STERILE DISPOSABLE: DO NOT RE-USE Manufactured by: OriGen Biomedical. OriGene VV13F Reinforced Dual Lumen Catheter indicated for use as a single cannula for both venous drainage and re-infusion of blood in the internal…
Category
Medical Device
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-628-2015·2015-04-29
Attix Pharmaceuticals Recalls Dextran-70 Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Dextran-70 active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Dextran-70 active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-513-2015·2015-04-29
Attix Pharmaceuticals Recalls Aminocaproic Acid Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Aminocaproic Acid active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Aminocaproic Acid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-762-2015·2015-04-29
Attix Pharmaceuticals Recalls Lidocaine HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Lidocaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Lidocaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-567-2015·2015-04-29
Attix Pharmaceuticals Recalls Cefazolin Sodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Cefazolin Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Cefazolin Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide